Jeff Castelli - Dec 21, 2022 Form 3 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
Chief Development Officer
Signature
/s/ Christian Formica, Attorney-in-Fact
Stock symbol
FOLD
Transactions as of
Dec 21, 2022
Transactions value $
$0
Form type
3
Date filed
12/30/2022, 08:12 PM
Next filing
Jan 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding FOLD Common Stock 304K Dec 21, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding FOLD Stock Options (right to buy) Dec 21, 2022 Common Stock 50K $12.28 Direct F2
holding FOLD Stock Options (right to buy) Dec 21, 2022 Common Stock 50K $9.03 Direct F2
holding FOLD Stock Options (right to buy) Dec 21, 2022 Common Stock 39.8K $15.67 Direct F2
holding FOLD Stock Options (right to buy) Dec 21, 2022 Common Stock 82.6K $10.04 Direct F3
holding FOLD Stock Options (right to buy) Dec 21, 2022 Common Stock 108K $9.55 Direct F4
holding FOLD Stock Options (right to buy) Dec 21, 2022 Common Stock 46.4K $21.78 Direct F5
holding FOLD Stock Options (right to buy) Dec 21, 2022 Common Stock 108K $12.11 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 161,910 Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of Amicus common stock.
F2 All of the options in this row are fully vested and exercisable as of December 21, 2022.
F3 The options reported in this row were granted on January 2, 2019 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 80,896 of such options were fully vested and exercisable and 1,748 remained unvested.
F4 The options reported in this row were granted on January 2, 2020 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 78,436 of such options were fully vested and exercisable and 29,139 remained unvested.
F5 The options reported in this row were granted on January 4, 2021 and become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 22,225 of such options were fully vested and exercisable and 24,171 remained unvested.
F6 The options reported in this row were granted on January 3, 2022 and will become exercisable in a series of installments over a four year period with 25% vesting on the one year anniversary of the grant date and remaining 75% vesting ratably each month thereafter. As of December 21, 2022, 0 of such options were fully vested and exercisable and 108,266 remained unvested.